Animal models have demonstrated that DPP-4 inhibitors improve glucose intolerance in early-stage diabetes, but not in the late stage of the disease [5], suggesting that DPP-4 inhibitors are more effective in the presence of functional β-cells. This evidence concerns the gene DPP4 and Glucose intolerance.